Colorectal Cancer News

New Phase II Trial for Patients with Untreated Metastatic Colorectal Cancer

This phase II clinical trial will evaluate a new antibody, MetMAb, targeting the c-met pathway, which is involved in the growth of cancer cells and is also involved with other growth factors that cancers use to survive. This trial will be randomized, which means that some patients will receive the MetMAb antibody plus FOLFOX/Bevacizumab and other patients will receive placebo plus FOLFOX/Bevacizumab. Patients will not know which combination they are receiving, but all patients will receive standard of care. Patients with metastatic colorectal cancer who have never received drug treatment may be eligible for this phase II trial.

To learn if you are eligible for this study, call the CCA’s Clinical Trial Matching Service at (866) 278-0392 to talk to a patient navigator.

Return